Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.70 |
| ▸ | LCK | P06239 | 8/20 | 0.70 |
| ▸ | TEK | Q02763 | 4/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.66 |
| ▸ | JAK3 | P52333 | 4/20 | 0.66 |
| ▸ | BRAF | P15056 | 4/20 | 0.66 |
| ▸ | DDR2 | Q16832 | 5/20 | 0.64 |
| ▸ | KIT | P10721 | 7/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | BCR | P11274 | 1/20 | 0.58 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.58 |
| ▸ | RAF1 | P04049 | 3/20 | 0.57 |
| ▸ | SRC | P12931 | 2/20 | 0.56 |
| ▸ | CSF1R | P07333 | 2/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13220068 | 0.86 | KDR (0.74) | KDRLCKTEKMAPK14JAK3 | |
| SCHEMBL13219723 | 0.85 | LCK (0.76) | KDRLCKTEKMAPK14JAK3 | |
| SCHEMBL3574810 | 0.82 | LCK (1.00) | KDRLCKTEKMAPK14DDR2 | |
| SCHEMBL5494114 | 0.82 | LCK (0.70) | KDRLCKTEKMAPK14JAK3 | |
| SCHEMBL13220047 | 0.82 | KDR (0.69) | KDRLCKTEKMAPK14JAK3 | |
| SCHEMBL4435452 | 0.81 | MAPK14 (0.68) | KDRLCKTEKMAPK14JAK3 | |
| SCHEMBL3932220 | 0.81 | DDR2 (0.73) | KDRLCKTEKMAPK14JAK3 | |
| SCHEMBL13220176 | 0.80 | MAPK14 (0.62) | KDRLCKTEKMAPK14JAK3 | |
| SCHEMBL5501133 | 0.80 | LCK (1.00) | KDRLCKTEKMAPK14JAK3 | |
| SCHEMBL5493948 | 0.80 | LCK (0.78) | KDRLCKTEKMAPK14JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776869-B2 | Heteroaryl-substituted alkyne compounds and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160283-A1 | HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE | IRAK3, IRAK1, MAP3K1 | KDR 666/4885LCK 108/4885TEK 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.